These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The role of nivolumab in melanoma. Gomes F; Serra-Bellver P; Lorigan P Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782 [TBL] [Abstract][Full Text] [Related]
8. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. Valsecchi ME N Engl J Med; 2015 Sep; 373(13):1270. PubMed ID: 26398077 [No Abstract] [Full Text] [Related]
9. The place of PD-1 inhibitors in melanoma management. Bowyer S; Lorigan P Lancet Oncol; 2015 Aug; 16(8):873-4. PubMed ID: 26115798 [No Abstract] [Full Text] [Related]
18. Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Melnikova VO; Bar-Eli M Pigment Cell Res; 2006 Oct; 19(5):395-405. PubMed ID: 16965268 [TBL] [Abstract][Full Text] [Related]
19. Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective. Goldstein DA; Zeichner SB Am J Manag Care; 2015 Sep; 21(10 Suppl):S234-41. PubMed ID: 26619297 [TBL] [Abstract][Full Text] [Related]
20. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Hersey P; Sosman J; O'Day S; Richards J; Bedikian A; Gonzalez R; Sharfman W; Weber R; Logan T; Buzoianu M; Hammershaimb L; Kirkwood JM; Cancer; 2010 Mar; 116(6):1526-34. PubMed ID: 20108344 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]